Moroni M - Search Results

1

Utility of embolization of chemoembolization as second-line treatment in patients with advanced or recurrent colorectal carcinoma.

Porta C, Moroni M, Nastasi G, Bobbio-Pallavicini E, Barazzoni G. Porta C, et al. Among authors: moroni m. Cancer. 1995 Jun 1;75(11):2782-4. doi: 10.1002/1097-0142(19950601)75:11<2782::aid-cncr2820751126>3.0.co;2-m. Cancer. 1995. PMID: 7743488 Clinical Trial. No abstract available.

2

5-methyltetrahydrofolate or 5-formyltetrahydrofolic acid to modulate 5-fluorouracil's cytotoxic activity in vivo. A phase II study in patients with advanced colon cancer.

Porta C, Moroni M, Epis O, Nastasi G. Porta C, et al. Among authors: moroni m. Cancer Chemother Pharmacol. 1996;38(2):195-7. doi: 10.1007/s002800050470. Cancer Chemother Pharmacol. 1996. PMID: 8616912 Clinical Trial.

3

Inhaled sodium cromoglycate to treat cough in advanced lung cancer patients.

Moroni M, Porta C, Gualtieri G, Nastasi G, Tinelli C. Moroni M, et al. Br J Cancer. 1996 Jul;74(2):309-11. doi: 10.1038/bjc.1996.358. Br J Cancer. 1996. PMID: 8688342 Free PMC article. Clinical Trial.

4

Epirubicin and etoposide combination chemotherapy to treat hepatocellular carcinoma patients: a phase II study.

Bobbio-Pallavicini E, Porta C, Moroni M, Bertulezzi G, Civelli L, Pugliese P, Nastasi G. Bobbio-Pallavicini E, et al. Among authors: moroni m. Eur J Cancer. 1997 Oct;33(11):1784-8. doi: 10.1016/s0959-8049(97)00163-9. Eur J Cancer. 1997. PMID: 9470833 Clinical Trial.

5

Folinic acid does improve 5-fluorouracil activity in vivo. Results of a phase III study comparing 5-fluorouracil to 5-fluorouracil and folinic acid in advanced colon cancer patients.

Bobbio-Pallavicini E, Porta C, Moroni M, Spaghi A, Casagranda I, Nastasi G. Bobbio-Pallavicini E, et al. Among authors: moroni m. J Chemother. 1993 Feb;5(1):52-5. doi: 10.1080/1120009x.1993.11739210. J Chemother. 1993. PMID: 8459266 Clinical Trial.

6

Possible efficacy of allopurinol vaginal washings in the treatment of chemotherapy-induced vaginitis.

Moroni M, Porta C. Moroni M, et al. Cancer Chemother Pharmacol. 1998;41(2):171-2. doi: 10.1007/s002800050725. Cancer Chemother Pharmacol. 1998. PMID: 9443632 No abstract available.

7

Nitrate plasma level as a marker of nitric oxide production after subcutaneous interleukin 2 immunotherapy.

Porta C, Moroni M, Bobbio-Pallavicini E, Tinelli C, Regazzi-Bonora M. Porta C, et al. Among authors: moroni m. J Natl Cancer Inst. 1997 Oct 15;89(20):1545. doi: 10.1093/jnci/89.20.1545. J Natl Cancer Inst. 1997. PMID: 9337353 Clinical Trial. No abstract available.

8

Doxorubicin/methotrexate/fluorouracil in advanced pancreatic cancer.

Porta C, Nastasi G, Spaghi A, Moroni M. Porta C, et al. Among authors: moroni m. Lancet. 1990 Dec 8;336(8728):1454-5. doi: 10.1016/0140-6736(90)93168-o. Lancet. 1990. PMID: 1978920 No abstract available.

9

5-Fluorouracil and d,l-leucovorin calcium are active to treat unresectable hepatocellular carcinoma patients: preliminary results of a phase II study.

Porta C, Moroni M, Nastasi G, Arcangeli G. Porta C, et al. Among authors: moroni m. Oncology. 1995 Nov-Dec;52(6):487-91. doi: 10.1159/000227516. Oncology. 1995. PMID: 7478436 Clinical Trial.

10

Nephrectomy as a component of systemic treatment for renal cell carcinoma patients.

Nastasi G, Porta C, Moroni M, Bobbio-Pallavicini E, Santagati G, Santagati C, Alessiani M. Nastasi G, et al. Among authors: moroni m. J Surg Oncol. 1994 Jun;56(2):81-2. doi: 10.1002/jso.2930560206. J Surg Oncol. 1994. PMID: 8007683 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

664 results

Search Page

Filters